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Abstract
Introduction Marfan syndrome is a genetic disorder affecting the connective tissue. Changes in lung tissue might influence 
respiratory function; however, a detailed respiratory functional assessment according to the need for major thoracic surgery 
is missing.
Methods Comprehensive pulmonary examinations were performed in 55 Marfan patients including respiratory symptoms, 
lung function (LF) testing using European Coal and Steel Community (ECSC) reference values,  TLCO and quality of life 
measurements. Groups included patients who did not need surgery (Mf, n = 32) and those who underwent major thoracic 
surgery  (Mfop, n = 23).
Results Respiratory symptoms affected 20% of patients. Scoliosis was significantly more frequent in the  Mfop group. LF 
demonstrated in all Marfan patients a tendency towards airway obstruction (FEV1/FVC = 0.77 ± 0.10), more prominent in 
 Mfop patients (0.74 ± 0.08 vs. Mf: 0.80 ± 0.11; p = 0.03). Correction of LF values using a standing height modification by 
arm span  (Hcorrected) revealed additional changes in FVC and FEV1.  TLCO and quality of life did not differ between groups.
Conclusions Marfan syndrome is associated with airway obstruction, especially in patients who have undergone major tho-
racic surgery, indicative of more severe connective tissue malfunction. The use of arm span for height correction is suitable 
to evaluate LF changes in this special patient group including patients with significant scoliosis.
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Introduction
Marfan syndrome is a systemic, autosomal dominantly 
inherited connective tissue disorder, first described in 1896 
by Antoine Marfan [1, 2]. In 1991, Francesco Ramirez iden-
tified the underlying changes in the glycoprotein fibrillin 1, 
encoded by the FBN1 gene, located on chromosome 15 at 
position 15q21.1 [3]. In approximately 25% of cases, a de 
novo mutation can be observed [4]. Fibrillin 1, a principal 
component of microfibrils, plays a key role in the forma-
tion and protection of the extracellular matrix [5]. Microfi-
brils support elastin deposition, and are therefore essential 
components of elastic fibres [6]. The prevalence of Mar-
fan disease is about 0.2 ‰ [7]. Since this condition is the 
consequence of connective tissue weakness, it has diverse 
symptoms. To ease the diagnostic process, the main symp-
toms have been collected to a unified nosology (Ghent cri-
teria, 1996) [7]. In 2010, a revision of the criteria abolished 
major and minor criteria and emphasised the value of genetic 
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testing [8]. Regarding lung manifestations, little information 
is available on the effects of connective tissue changes in 
the respiratory system; only a few pleuropulmonary abnor-
malities are known. Chest deformities or dissection of the 
ascending aorta can affect the mechanics of the ventilatory 
pump. Structural changes to the lungs can lead to apical 
blebs and bullae or result in spontaneous pneumothorax [9, 
10]. Sleep apnoea is also observed as a consequence of the 
involvement of the upper airways [11].
Lung function (LF) values measured by spirometry and 
plethysmography are influenced by thoracic structures such 
as the airways, lung parenchyma, pleura and muscles; thus, 
functional changes in LF parameters used in routine clini-
cal practice might be influenced by Marfan syndrome [12]. 
However, the reference values used in patients with the spe-
cial body measurements characteristic of Marfan syndrome 
can be misleading, and comparative measures are lacking 
[13, 14] . In the present study, our aim was to assess changes 
to the respiratory system in this rare inherited connective 
tissue disorder using different reference equations.
Materials and Methods
Study Subjects
The study had a cross-sectional design. Following a written 
inquiry, 55 Caucasian patients from the National Marfan 
Registry (established and supervised by the Hungarian Mar-
fan Foundation) agreed to participate in the study. Patients 
were diagnosed with Marfan syndrome using the revised 
Ghent nosology [8] and/or genetic confirmation (Table 3).
Study Design
Pulmonary examinations were voluntary. After signing 
the informed consent, a detailed respiratory assessment 
was carried out in the Department of Pulmonology, Sem-
melweis University, Budapest, Hungary between the 31 
March 2015 and 4 September 2017. Exclusion criteria 
were age < 16 years old and major thoracic surgery within 
6 months before the assessment. Major thoracic surgery was 
usually prophylactic aortic root surgery [15, 16] or chest wall 
surgery and spine correction.
Data on respiratory symptoms (dyspnoea, cough, 
sputum, chest pain), smoking history, sex, age, height, 
bodyweight, body mass index (BMI) and arm span (cm) 
were collected. All patients underwent arterialised ear-
lobe blood gas analysis (Cobas b 221, Roche, Budapest, 
Hungary), chest X-ray and fluoroscopy, laboratory testing 
and electrocardiography. The 6-minute walk test (6MWT) 
was performed to measure exercise capacity according to 
American Thoracic Society (ATS) guidelines [17]. The 
extent of scoliosis was measured according to the Cobb 
method [18]. To assess general quality of life (QoL), the 
QoL Visual Analogue Scale (VAS) was used. To iden-
tify patient health-related conditions, the COPD Assess-
ment Test (CAT®, Hungarian version) [19] and modified 
Medical Research Council Dyspnoea Scale (mMRC) were 
applied [20].
The study protocol was approved by the Semmelweis 
University Regional and Institutional Committee of Sci-
ence and Research Ethics (TUKEB 165/2016) in accord-
ance with the Declaration of Helsinki.
Lung Function Measurements
LF measurements included forced vital capacity (FVC), 
forced expiratory volume in the first second (FEV1), 
FEV1/FVC, forced expiratory flow between 25 and 75% 
of FVC (FEF25–75), total lung capacity (TLC), residual 
volume (RV) and functional residual capacity (FRC) by 
means of electronic spirometer and body plethysmogra-
phy (PDD-301/s, Piston, Budapest, Hungary) according 
to the European Respiratory Society and ATS guidelines 
[12]. Three technically acceptable manoeuvres were per-
formed and the highest value of them was used. Transfer 
factor  (TLCO) and coefficient  (KLCO) of the lung for car-
bon monoxide were measured with single breath method 
(PDD-301/s, Piston, Budapest, Hungary). LF variables are 
expressed as percentage of predicted values.
As baseline reference values, we used the database of 
the European Coal and Steel Community (ECSC) set by 
the spirometry manufacturer [21]. ECSC is used in all 
Hungarian lung function laboratories. ECSC spirometry 
reference calculations are the following: FVC men: 5.76H 
- 0.026A - 4.34; FVC women: 4.43H - 0.026A - 2.89 and 
FEV1 men: 4.30H - 0.029A - 2.49; FEV1 women: 3.95H 
- 0.025A - 2.69; (H—height, A—age).
Reference equations using measured height  (Hmeasured), 
age and gender may be inappropriate in Marfan syndrome 
patients due to their special skeletal features, especially 
following thoracic surgery. To overcome these thoracic 
abnormalities, we used arm span to correct for height 
 (Hcorrected) [22]. For homogeneous Caucasian populations, 
the following equations are recommended by Parker et al. 
[23]:
Males:  Hcorrected (m) = 68.74 + 0.63008·Arm span 
(m) − 0.1019A.
Females:  Hcorrected (m) = 33.14 + 0.79499·Arm span (m).
We recalculated the spirometric values based on  Hcorrected 
by applying the original ECSC equations. The range of accu-
racy in the recommendations for forced expiratory manoeu-
vres FVC and FEV1 is ± 3% of reading or ± 0.050 L, which-
ever is greater [12].
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Statistical Analysis
Statistical analysis was performed with GraphPad soft-
ware (Graph Pad Prism 5.0 by Graph Pad Software Inc., 
San Diego, USA). Data are presented as mean and stand-
ard deviation for continuous data and as median and range 
for categorical data, respectively. Differences between 
groups for parametric data were compared using Student’s 
t test, while Fisher’s exact test was applied for analysing 
non-parametric data. Pearson correlation was performed 
to test connection between the degree of scoliosis and 
lung function values. In all cases, p < 0.05 was considered 
statistically significant.
Results
Patient characteristics are summarised in Table 1. The aver-
age age was 38.1 ± 13.1 years. Most patient were never 
smokers. In the  Mfop group, patients had undergone major 
thoracic surgery mainly due to cardiac causes. Height cor-
rection resulted in significantly lower values in Mf patients; 
however, this difference was only observed in men.
Chest deformities and respiratory symptoms are sum-
marised in Table 2. Significantly more patients suffered 
from scoliosis in the  Mfop group. Significant negative 
correlation between the extent of scoliosis and FVC% 
(r =  − 0.414, [95% CI − 0.617 to − 0.159], p = 0.0023) and 
FEV1% (r =  − 0.401, [95% CI − 0.607 to − 0.144], p = 0.003) 
were noted. Similarly,  Hcorrected FVC% (r =  − 0.463, [95% 
Table 1  Patient characteristics
a Significant difference compared to the value above
All patients (n = 55) Mf group (n = 32) Mfop group (n = 23) p value Mf versus  Mfop
Age (years) 38.1 ± 13.1
 Men 32.6 ± 11.6 32.4 ± 11.0 33.9 ± 11.1 n.s
 Women 40.8 ± 13.2a 37.9 ± 10.9 45.1 ± 14.8 n.s
Gender
 Men, n (%) 20 (36) 11 (34) 9 (39) n.s
 Women, n (%) 35 (64) 21 (66) 14 (61) n.s
Weight (kg) 71.7 ± 17.5
 Men 79.1 ± 22.2 79.8 ± 20.3 80.4 ± 23.3 n.s
 Women 67.1 ± 12.2 68.1 ± 14.5 67.4 ± 8.9 n.s
Height (m)
 (a) Measured 182.3 ± 10.0 183.1 ± 8.5 181 ± 11.8 n.s
 (b) Corrected 179.5 ± 7.4a 180.4 ± 6.4a 177 ± 8.4 n.s
 Men
  a. Measured 191.7 ± 7.9 191.6 ± 9.1 191.7 ± 7.3 n.s
  b. Corrected 186.3 ± 6.5 187.0 ± 6.6a 185.2 ± 6.6 n.s
 Women
  a. Measured 176.5 ± 6.2 178.6 ± 3.6 1.73.9 ± 8.3 n.s
  b. Corrected 176.0 ± 5.0 177.3 ± 3.2 174.0 ± 6.6 n.s
BMI (kg/m2) 21.5 ± 4.5
 Men 21.5 ± 5.7 21.1 ± 4.7 23.0 ± 6.2 n.s
 Women 21.5 ± 3.7 21.1 ± 4.4 22.3 ± 2.8 n.s
Arm span (cm) 185.1 ± 9.3
 Men, n (%) 191.8 ± 10.2 193.0 ± 10.2 190.3 ± 9.9 n.s
 Women, n (%) 181.7 ± 6.8 183.3 ± 4.4 179.1 ± 8.7 n.s
Smoking habit
 Never smoker, n (%) 40 (73) 25 (78) 15 (65) n.s
 Former smoker, n (%) 11 (20) 5 (16) 6 (26) n.s
 Current smoker, n (%) 4 (7) 2 (6) 2 (9) n.s
Major thoracic surgery indication
 Cardiac, n (%) 19 (35) 0 19 (35) Not analysed
 Chest or spine deformity, n (%) 4 (7) 0 0
468 Lung (2019) 197:465–472
1 3
Table 2  Chest deformities and respiratory symptoms in patients with Marfan syndrome
FBN1 Fibrillin 1
All patients 
(n = 55)
Mf group (n = 32) Mfop group (n = 23) p value 
Mf versus 
 Mfop
Chest deformities
 Pectus carinatum, n (%) 24 (48) 12 (38) 12 (52) n.s
 Pectus excavatum, n (%) 14 (28) 6 (19) 6 (26) n.s
 Scoliosis, n (%) 36 (72) 15 (47) 21 (91)  < 0.01
 Asymmetric chest, n (%) 19 (38) 11 (34) 8 (35) n.s
Structural abnormalities of the lung
 Spontaneous pneumothorax, n (%) 5 (10) 3 (9) 2 (9) n.s
 Apical blebs and bullae, n (%) 4 (8) 3 (9) 1 (4) n.s
Pleuropulmonary symptoms
 Cough, n (%) 11 (20) 5 (16) 6 (26)  < 0.01
 Sputum, n (%) 5 (9) 1 (3) 4 (17) n.s
 Dyspnoea, n (%) 10 (18) 3 (9) 7 (30)  < 0.01
 Chest pain, n (%) 9 (16) 2 (6) 7 (30) 0.03
Ghent nosology, n (%)
 Dilatation of the ascending aorta 38 (69) 20 (61) 18 (78) n.s
 Dissection of the ascending aorta 7 (13) 2 (7) 5 (22) n.s
 Mitral valve prolapse 48 (87) 28 (87) 20 (86) n.s
 Dilatation or dissection of descending aorta 1 (2) 0 (0) 1 (6) n.s
 Reduced upper-to-lower segment ratio 8 (14) 5 (16) 3 (12) n.s
 Increased arm span-to-height ratio 8 (15) 4 (14) 4 (17) n.s
 Wrist sign 47 (85) 29 (90) 18 (79) n.s
 Thumb sign 51 (92) 28 (86) 23 (100) n.s
 Reduced extension at the elbows 5 (9) 1 (3) 4 (18) n.s
 Medial displacement of the medial malleolus caus-
ing pes planus
30 (55) 16 (52) 14 (61) n.s
 Heel deformity 8 (15) 5 (17) 3 (12) n.s
 Protrusio acetabulae of any degree 1 (2) 1 (3) 0 (0) n.s
 Joint hypermobility 29 (52) 17 (52) 12 (53) n.s
 Highly arched palate with crowding of teeth 35 (63) 20 (62) 15 (65) n.s
 Facial appearance 35 (63) 19 (59) 16 (68) n.s
 Dolichocephaly 11 (20) 5 (17) 6 (24) n.s
 Enophthalmos 12 (22) 7 (21) 6 (24) n.s
 Downslanting palpebral fissures 9 (17) 7 (21) 3 (12) n.s
 Malar hypoplasia 8 (15) 4 (14) 4 (18) n.s
 Retrognathia 17 (30) 8 (24) 9 (41) n.s
 Ectopia lentis 15 (28) 7 (23) 8 (35) n.s
 Myopia over 3 diopters 29 (52) 16 (50) 13 (56) n.s
 Increased axial length of the globe 3 (6) 2 (7) 1 (6) n.s
 Hypoplastic iris or hypoplastic ciliary muscle caus-
ing decreased miosis
1 (2) 0 (3) 0 (0) n.s
 Lumbosacral dural ectasia 4 (7) 4 (10) 0 (0) n.s
 Striae atrophicae (stretch marks) 36 (66) 22 (69) 14 (61) n.s
 Positive family history 32 (58) 18 (56) 14 (60) n.s
 Sex (male) 20 (36) 11 (34) 9 (39) n.s
 Systemic score 8 ± 2 8 ± 2 8 ± 2 n.s
 FBN1 mutation identified 40 (73) 21 (62) 19 (84) n.s
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CI − 0.661 to − 0.206], p < 0.001) and FEV1% (r =  − 0.386, 
[95% CI − 0.599 to − 0.125], p = 0.005) confirmed the asso-
ciation (Fig. 1.).
Respiratory symptoms were present in fewer than 20% of 
patients. Dyspnoea, cough and chest pain were significantly 
more frequent  Mfop patients. Structural changes assessed by 
chest CT scans of the lungs were scarce.
The LF data using the ECSC reference and  Hmeasured are 
summarised in Table 3.  Mfop patients had significantly lower 
FVC, IVC (inspiratory vital capacity) and TLC as com-
pared to Mf patients. FEV1/FVC was 0.74 ± 0.08 in  Mfop 
and 0.80 ± 0.11 in Mf patients, suggesting an obstructive 
ventilatory pattern in operated patients. Obstruction severity 
in  Mfop, expressed as % predicted FEV1, corresponded to 
moderate changes. Airway obstruction in  Mfop patients was 
confirmed by significantly decreased FEF25–75 values as 
compared to Mf patients. Increased RV and FRC, both signs 
of hyperinflation, were observed in both groups.
Diffusion  (TLCO and  KLCO), blood gases, 6MWT data or 
QoL were not different between groups (Table 3). CAT® and 
mMRC showed higher values in the  Mfop group with more 
respiratory symptoms.
Using arm span corrected height, FVC and FEV1% 
predicted values increased in all patient groups (Table 4.). 
FEV1 remained in the pathological range in Mfop patients 
( < 80% predicted) and stayed significantly lower as com-
pared to Mf group.
Discussion
Our study is the largest cohort of Marfan patients who were 
serially assessed for pulmonary involvement. Twenty per-
cent of the patients complained about pulmonary symptoms. 
Cough, dyspnoea and chest pain were common, affecting a 
higher proportion of  Mfop patients. QoL measures correlated 
with symptoms.
LF values are usually based on age, sex and standing 
height, which may be misleading in Marfan syndrome, 
where the length of the lower limbs contributes dispropor-
tionally to height [24]. As height can be corrected by arm 
span, we used equations to overcome this height measure-
ment bias. This resulted in a significant decrease in the 
height values of Mf group patients, especially in men, lead-
ing to the conclusion that, in many Marfan patients, standard 
LF reference values are disproportionally high.
In 1960, the ECSC was the first organisation to issue rec-
ommendations for the calculation of reference values [25]. 
The reference values described by the ECSC were based on 
males working in coal mines and steel works. This was not 
a representative reference population, and in practice the 
predicted values were considered to be too high. Although 
no women had been tested, the ECSC calculated reference 
values for females at 80% of the values for men [14].
Our data confirmed airway obstruction, mainly affect-
ing the small airways, in all Marfan patients. Similar results 
were previously observed in a study by Streeten and al [26]. 
The novelty of our study is the subgrouping according to 
major thoracic surgery. It is of high clinical importance to 
ensure appropriate lung function during or following exten-
sive thoracic interventions. As a majority of  Mfop patients 
had scoliosis, it is not surprising that the measured and 
corrected heights did not differ in these patients. However, 
height correction revealed abnormal FVC and FEV1 values.
Airway obstruction was moderate in all patients. This 
change might result from connective tissue malfunction 
in this young patient population due to their disease. The 
changes might also reflect incipient emphysema and/or an 
increased tendency for the airways to collapse [27]. Due to 
the pathological structure of fibrillin 1, the development of 
emphysema can be often observed in these patients. Rob-
besom et al. showed that aberrant fibrillin 1 in the lung is 
significantly associated with the three most important mor-
phometric parameters of emphysema: alveolar destruction, 
airspace enlargement and emphysema-related morphologi-
cal abnormalities; [28] experimental data in mice have con-
firmed widening of the distal airspaces in Marfan syndrome 
[29]. As described by Hogg et al., small airways are the main 
site of obstruction in lungs affected by emphysema [30]. It 
is suspected that areas with trapped air develop emphysema 
over time [31]. Combined with the increased tendency of 
the small airways to collapse in Marfan syndrome [27], it 
Fig. 1  Correlation between 
extent of scoliosis and height 
corrected FVC% (a) and 
FEV1% (b)
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Table 3  Lung function testing 
in Mf and  Mfop using  Hmeasured 
for the ECSC equations
FVC forced vital capacity, FEV1 forced expiratory volume in the first second, FEF25–75 forced expiratory 
flow between 25 and 75%, PEF peak expiratory flow, RV residual volume, FRC functional residual capac-
ity, TLC total lung capacity
a Data expressed as median (range)
All patients (n = 55) Mf group (n = 32) Mfop group (n = 23) p value 
Mf versus 
 Mfop
FVC (L) 4.20 ± 1.10 4.53 ± 1.06 3.75 ± 1.02 0.01
FVC (%) 93.38 ± 17.54 97.55 ± 15.66 86.48 ± 18.05 0.02
FEV1 (L) 3.24 ± 0.10 3.60 ± 0.93 2.76 ± 0.79  < 0.01
FEV1 (%) 84.13 ± 18.52 91.06 ± 17.02 75.06 ± 16.69  < 0.01
FEF25–75 (L) 2.96 ± 1.24 3.40 ± 1.20 2.35 ± 0.99  < 0.01
FEF25–75 (%) 71.49 ± 29.50 80.32 ± 31.16 59.40 ± 21.18 0.01
PEF (L) 6.25 ± 1.72 6.56 ± 1.63 5.90 ± 1.81 n.s
PEF (%) 74.25 ± 18.08 77.39 ± 18.77 70.99 ± 16.79 n.s
RV (%) 125.86 ± 30.42 128.45 ± 34.67 124.03 ± 27.01 n.s
FRC (%) 122.70 ± 26.42 120.85 ± 27.66 124.03 ± 25.45 n.s
TLC (L) 5.90 ± 1.26 6.27 ± 1.20 5.41 ± 1.20 0.01
TLC (%) 87.83 ± 14.51 92.97 ± 11.41 82.57 ± 16.33  < 0.01
IVC (L) 4.16 ± 1.08 4.43 ± 1.06 3.80 ± 1.03 0.03
IVC (%) 87.25 ± 16.82 91.27 ± 15.29 82.72 ± 17.82 0.05
FEV1/FVC 0.77 ± 0.10 0.80 ± 0.11 0.74 ± 0.08 0.03
FEV1/IVC 0.80 ± 0.16 0.82 ± 0.12 0.71 ± 0.18  < 0.01
TLCO (mmol/min/kPa) 10.01 ± 2.83 10.74 ± 2.82 9.24 ± 2.68 n.s
TLCO (%) 89.55 ± 18.43 94.64 ± 17.97 85.17 ± 18.02 n.s
KLCO [mmol/min/kPa/L] 1.72 ± 0.32 1.77 ± 0.30 1.68 ± 0.34 n.s
KLCO (%) 80.57 ± 17.11 80.69 ± 19.00 81.50 ± 14.68 n.s
Blood gases
 pH 7.42 ± 0.02 7.41 ± 0.02 7.42 ± 0.01 n.s
 pO2 (mmHg) 83.28 ± 7.02 83.88 ± 6.24 82.41 ± 8.09 n.s
 pCO2 (mmHg) 37.42 ± 3.21 37.13 ± 0.02 37.84 ± 3.19 n.s
6MWT
 Distance (m) 566.7 ± 99.06 584.28 ± 92.82 542.22 ± 104.27 n.s.
 Heart rate change (1/min) 34.40 ± 12.65 40.03 ± 11.20 26.57 ± 7.43 n.s.
 O2 saturation change (%) 1.02 ± 8.36 1.53 ± 2.4 0.30 ± 1.36 n.s.
QoL
 VAS (1–100) 78.39 ± 19.67 81.37 ± 18.01 74.16 ± 21.61 n.s
 CAT (0–40)a 7 (0–22) 7 (0–22) 10 (0–22) n.s
 mMRC (0–4)a 0 (0–3) 0 (0–2) 1 (0–3) n.s
Table 4  Lung function 
parameters using ECSC with 
 Hmeasured and  Hcorrected in Marfan 
patients
All patients (n = 55) Mf group (n = 32) Mfop group (n = 23) p value 
Mf versus 
 Mfop
FVC%
 ECSC  Hmeasured (%) 93.38 ± 17.54 97.55 ± 15.66 86.48 ± 18.05 0.02
 ECSC  Hcorrected (%) 96.68 ± 18.09 101.99 ± 15.18 88.02 ± 19.15 0.01
FEV1%
 ECSC  Hmeasured (%) 84.13 ± 18.52 91.06 ± 17.02 75.06 ± 16.69  < 0.01
 ECSC  Hcorrected (%) 86.41 ± 23.49 93.27 ± 16.68 77.25 ± 18.92  < 0.01
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can be assumed that, due to connective tissue malfunction, 
air trapping starts in the small airways, which later might 
convert into emphysema.
Six of our patients (10,9%) were diagnosed with asthma, 
5 of them well controlled (Mf n = 3, Mfop n = 2) without 
obstructive ventilatory changes at the time of assessment. 
One patient awaiting cardiac surgery presented with mixed 
ventilatory pattern. No further patients had clinical signs 
of asthma. The extent of scoliosis showed significant nega-
tive correlation with FVC% and FEV1%, pointing towards 
restrictive changes due to thorax abnormalities.
Our data suggest that LF evaluation in patients with atypi-
cal anthropometrical features can be difficult. The equations 
applied in LF testing might give different results and it might 
be beneficial to reassess results in those who have unusual 
physical features.
Conclusion
This study performed a complex respiratory functional 
assessment of a large cohort of Marfan patients, confirming 
previous data showing mild obstructive ventilatory disorder. 
The need for major thoracic surgery was associated with 
more respiratory symptoms, more severe functional changes 
and worse QoL. Height correction revealed decreased FVC 
and FEV1 values in  Mfop patients more in line with their 
clinical symptoms. Small airway obstruction in our patients 
indicates that particular attention is needed in the follow-up 
of respiratory status. One weakness of our study is that the 
reversibility of airway obstruction in  Mfop patients was not 
investigated in the absence of clinical symptoms of asthma. 
The extent of scoliosis showed significant negative cor-
relation with FVC% and FEV1% suggestive of restrictive 
changes due to thoracic deformities. Longitudinal data will 
be needed to evaluate changes of airway function in Marfan 
syndrome. In daily clinical practice, more attention should 
be placed on pulmonary involvement and LF assessments 
when planning or after major thoracic surgery in Marfan 
patients.
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